ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

E. Thunnissen*, B. Lissenberg-Witte, M. M. van den Heuvel, K. Monkhorst, B. G. Skov, J. B. Sorensen, A. Mellemgaard, A. M. C. Dingemans, E. J. M. Speel, A. J. de Langen, S. M. S. Hashemi, I. Bahce, M. A. van der Drift, M. G. Looijen-Salamon, J. Gosney, P. E. Postmus, S. M. S. Samii, F. Duplaquet, B. Weynand, X. DurandoF. Penault-Llorca, S. Finn, A. O. Grady, B. Oz, N. Akyurek, R. Buettner, J. Wolf, L. Bubendorf, S. Duin, L. Marondel, L. C. Heukamp, W. Timens, E. M. D. Schuuring, P. Pauwels, E. F. Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)13-18
Number of pages6
JournalLung Cancer
Volume138
DOIs
Publication statusPublished - Dec 2019

Keywords

  • non-small cell lung cancer
  • alk
  • immunohistochemistry
  • fluorescence in situ hybridisation
  • treatment
  • prognosis
  • MOLECULAR TESTING GUIDELINE
  • KINASE INHIBITORS GUIDELINE
  • OF-AMERICAN-PATHOLOGISTS
  • LUNG-CANCER PATIENTS
  • INTERNATIONAL-ASSOCIATION
  • COPY NUMBER
  • REARRANGEMENT
  • IHC
  • ADENOCARCINOMA
  • PREVALENCE

Cite this